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The HIF-pathway inhibitor NSC-134754 induces metabolic
changes and anti-tumour activity while maintaining
vascular function
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BACKGROUND: Hypoxia-inducible factor-1 (HIF-1) mediates the transcriptional response to hypoxic stress, promoting tumour
progression and survival. This study investigated the acute effects of the small-molecule HIF-pathway inhibitor NSC-134754.
METHODS: Human PC-3LN5 prostate cancer cells were treated with NSC-134754 for 24 h in hypoxia. Orthotopic prostate tumour-
bearing mice were treated with a single dose of NSC-134754 for 6, 24 or 48 h. Treatment response was measured using magnetic
resonance spectroscopy and imaging. Ex-vivo histological validation of imaging findings was also sought.
RESULTS: In vitro, NSC-134754 significantly reduced lactate production and glucose uptake (Po0.05), while significantly increasing
intracellular glucose (Po0.01) and glutamine uptake/metabolism (Po0.05). Increased glutamine metabolism was independent of
c-Myc, a factor also downregulated by NSC-134754. In vivo, a significantly higher tumour apparent diffusion coefficient was
determined 24 h post-treatment (Po0.05), with significantly higher tumour necrosis after 48 h (Po0.05). NSC-134754-treated
tumours revealed lower expression of HIF-1a and glucose transporter-1, at 6 and 24 h respectively, while a transient increase in
tumour hypoxia was observed after 24 h. Vessel perfusion/flow and vascular endothelial growth factor levels were unchanged with
treatment.
CONCLUSION: NSC-134754 induces metabolic alterations in vitro and early anti-tumour activity in vivo, independent of changes in
vascular function. Our data support the further evaluation of NSC-134754 as an anti-cancer agent.
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Solid tumours typically exhibit hypoxic regions that are associated
with a more aggressive phenotype, impacting negatively on
treatment response and patient survival (Gray et al, 1953; Vaupel
et al, 2004; Tatum et al, 2006). A key mediator of hypoxic cell
survival and adaptation is the hypoxia-inducible factor-1 (HIF-1)
pathway (Semenza, 2000). Hypoxia-inducible factor-1 is a hetero-
dimeric transcription factor composed of the oxygen-labile HIF-
1a, and constitutively expressed HIF-1b subunits. In response to
hypoxia, HIF-1a is stabilised allowing dimerisation with HIF-1b to
form the HIF-1 complex (Wang and Semenza, 1995). Translocation
of HIF-1 to the nucleus and binding to hypoxic response elements
leads to the transcription and translation of numerous genes
(Semenza et al, 1994; Carmeliet et al, 1998; Pugh and Ratcliffe,
2003). Importantly, many of the upregulated genes have recognised
functions in tumourigenesis, modulating tumour metabolism, and
enhancing angiogenesis, invasion and metastasis (Maxwell et al,
1997; Semenza, 2003; Robey et al, 2005). Given the diversity of the
pathogenic pathways involved, compounds that target HIF-1 or
components of the HIF pathway are actively being sought, and
several small-molecule inhibitors of the HIF pathway are currently
in clinical trials (Onnis et al, 2009; Tennant et al, 2010).
To assist in the evaluation of novel HIF inhibitors, reliable,
reproducible and informative biomarkers capable of assessing
tumour response are required. Magnetic resonance imaging (MRI)
is one non-invasive technique used clinically to investigate tumour
response to a wide range of cancer therapeutics. Conventionally,
the response evaluation criteria in solid tumours (RECIST)
imaging criteria denotes the assessment of tumour volume in
response to various interventions over time. However, evidence is
emerging that novel targeted therapeutics may elicit efficacy before
any reduction in tumour volume, and that the measurement of
acute functional changes in tumour pathophysiology in vivo may
be more revealing (Michaelis and Ratain, 2006). In this regard,
functional imaging techniques such as dynamic contrast-enhanced
MRI (DCE-MRI), which reports on tumour vascular permeability/
perfusion, and diffusion-weighted MRI (DW-MRI), used to assess
tissue cellularity and necrosis, are being extensively used to
evaluate tumour therapeutic response in both pre-clinical and
clinical trials (Leach et al, 2005; Padhani et al, 2009). In addition,
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magnetic resonance spectroscopy (MRS) can provide a quantita-
tive snapshot of cellular metabolism, allowing an insight into
therapy-induced shifts in energy pathways and metabolic con-
sumption (Griffiths et al, 2002; Beloueche-Babari et al, 2010). The
use of MRI/MRS to investigate novel pharmacological HIF
inhibitors, and with it increase understanding and context of
potential clinical application, is gaining momentum (Jordan et al,
2005a; Jordan et al, 2005b).
In this study, we have used several MR techniques to investigate
acute response of human prostate cancer cells to the HIF-pathway
inhibitor NSC-134754 in vitro, and in a murine orthotopic prostate
model in vivo. NSC-134754 was previously identified from a
cell-based screening assay as a translational inhibitor of HIF-1 in
response to both hypoxic stress and growth-factor-mediated path-
ways (Chau et al, 2005). In vivo, NSC-134754 has demonstrated pre-
clinical anti-tumour activity in a mouse model of human
glioblastoma, inducing tumour shrinkage post-irradiation during a
3-week treatment regime, with continued shrinkage observed post-
treatment until experiment end (Kioi et al, 2010). Treatment
response to NSC-134754 in human prostate carcinoma has not yet
been reported. We demonstrate the utility of MRS and MRI in
assessing the metabolic effects of HIF-pathway inhibition with NSC-
134754 in human prostate cells in vitro, and acute functional
changes in orthotopic prostate xenografts in vivo. Complementary
techniques to validate the activity of NSC-134754 were also sought,
including effects on cellular proliferation and expression of HIF-1a
and the downstream targets vascular endothelial growth factor
(VEGF) and glucose transporter-1 (GLUT-1). Additionally, changes
in the tumour microenvironment induced by NSC-134754 on
tumour perfusion, hypoxia and necrosis were also investigated.
MATERIALS AND METHODS
Cell culture and hypoxic conditions
Human PC-3LN5 prostate tumour cells were a kind gift from Dr S
Eccles (Cancer Therapeutics Unit, Institute of Cancer Research).
These cells were originally generated in-house from the lymph
node metastases of orthotopic PC-3 tumours grown in male NCr
nude mice (Sanderson et al, 2006). Cells were maintained in RPMI
1640 media supplemented with 10% (v/v) fetal bovine serum
(Gibco by Invitrogen, Paisley, UK) at 37 1C in a humidified
incubator with an atmosphere of 5% CO2 in 95% air. In-vitro
experiments were performed under hypoxia, with cells plated and
allowed to adhere in normoxic conditions before incubation in a
humidified hypoxic workstation (Hypoxystation, Don Whitley
Scientific, Shipley, UK), pre-equilibrated to 1.0% O2, 5% CO2.
Drug preparation
NSC-134754 was obtained from the National Cancer Institute’s
Developmental Therapeutics Program (MD, USA). For in-vitro
experiments, dilutions were prepared in culture medium on
the day of the experiment from frozen 1mM stock. For in-vivo
experiments, 30mgml 1 NSC-134754 was freshly prepared in
0.9% NaCl before intraperitoneal injection.
Sulforhodamine B assay
The sulforhodamine B assay was performed to measure the effects
of NSC-134754 on cell proliferation and establish the GI50 inhibition
of cell growth (the concentration needed to reduce the growth of
treated cells to half that of untreated cells). Cells were incubated in
100ml medium in 96-well plates (Corning Incorporated, Corning,
NY, USA) for 48 h before the addition of 100 ml drug-containing
medium. Final concentrations of NSC-134754 ranged from 0.0012
to 10mM in a final volume of 200 ml. Fixation and staining followed
the standard method developed by Skehan et al (1990).
Western blot analysis
Whole cell lysates were prepared and analysed for western blotting
as described previously (Bardos and Ashcroft, 2004). A minor
modification included harvesting cells in RIPA buffer (Cell
Signaling, Boston, MA, USA) supplemented with 1 complete
protease inhibitor (Roche Applied Sciences, Burgess Hill, UK) for
protein determination and GLUT-1, LDH-A and c-Myc analysis.
Antibodies used included anti-human HIF-1a (clone 54, BD
Transduction Laboratories, Lexington, KY, USA, 1 : 500), anti-
human GLUT-1 (Millipore, Billerica, MA, USA, 1 : 100), anti-
human LDH-A (Santa Cruz Biotechnology, Santa Cruz, CA,
USA, 1 : 3000) and anti-c-Myc (Cell Signaling, 1 : 3000). b-Actin
(GE Healthcare, Buckinghamshire, UK, 1 : 5000) was detected and
used as a loading control. For positive assay controls, deferoxamine-
induced PC-3LN5 cell lysates (16h treatment) were used for HIF-1a
and LDH-A, deferoxamine-induced HCT116 human colon carcinoma
cell lysates (16h treatment) for c-Myc, and normal mouse brain for
GLUT-1. Following c-Myc and LDH-A determination, immuno-
blots were stripped using re-blot stripping buffer (Millipore) and
reprobed with anti-b-actin antibody as described above. Anti-
mouse (1 : 5000), anti-rabbit (1 : 2000) and anti-goat (1 : 10 000)
horseradish peroxidise-conjugated secondary antibodies were
used, with subsequent detection using the chemiluminescent
substrate ECLþ (all GE Healthcare).
GLUT-1 immunocytofluorescence
PC-3LN5 cells were seeded in six-well plates (Corning Incorporated)
using 20 20mm2 coverslips and allowed to adhere overnight.
The following day, the medium was replaced with either fresh or
NSC-134754 supplemented medium for 30min before exposure to
hypoxic (1% O2) conditions. After incubation, the cells were rinsed
in PBS and fixed with ice-cold methanol for 5min. Non-specific
binding was blocked with 5% donkey serum (Sigma-Aldrich,
Poole, UK) followed by incubation for 90min with goat anti-human
GLUT-1 (Santa Cruz Biotechnology, 1 : 100). After several washes,
cells were incubated for 1 h, protected from light, with Dylight549-
conjugated donkey anti-goat antibody (Jackson Immunoresearch,
West Grove, PA, USA, 1 : 200). Nuclei were counterstained with
DAPI (Sigma-Aldrich), mounted with vectashield (Vector Labora-
tories, Peterborough, UK) and imaged with a BX51 microscope
(Olympus Optical, London, UK) interfaced to a PC running by
CellP (Soft Imaging System, Mu¨nster, Germany).
MRS of cell extracts and media
Semi-confluent PC-3LN5 cells plated in T75 cm2 flasks (Corning
Incorporated) were treated with 7.5 mM NSC-134754 (5  GI50),
and subsequently harvested following 24 h in hypoxia (1% O2).
Cells were washed with ice-cold PBS and fixed with ice-cold
methanol. After 10min, adherent cells were removed by mecha-
nical scraping and metabolites were extracted from cells using a
dual-phase extraction method (Tyagi et al, 1996). Samples were
freeze-dried, resuspended in D2O and analysed using
1H-MRS.
Conditioned cell culture medium was also collected and analysed
by 1H-MRS. The internal standard sodium 3-trimethylsilyl-2,2,3,3-
tetradeuteropropionate (TSP) was added to the samples for chemical
shift calibration and quantification. 1H-MR spectra were acquired
on a 500-MHz Bruker spectrometer (Ettlingen, Germany). A pulse
and acquire with water suppression MR sequence was used (pulse
angle of 451, repetition time of 3 s, 256 averages (64 averages for
media samples), spectral width of 7500Hz). Metabolite concentra-
tions were determined through the summation of all resonance
integrals to which each metabolite contributes, using the Bruker
Topspin-2 NMR software package, normalised relative to the peak
integral of the internal reference TSP and cell number.
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Propagation of tumour xenografts
All experiments were performed in accordance with the local
ethical review panel, the UK Home Office Animals (Scientific
Procedures) Act 1986, and the United Kingdom Co-ordinating
Committee on Cancer Research guidelines (Workman et al, 2010).
Male NCr nude mice were injected orthotopically with 1 105
PC-3LN5 cells in 50 ml serum-free medium into the ventral prostate
gland. Tumours were selected for imaging when they reached a
volume of B1 cm in diameter (assessed by palpation).
Magnetic resonance imaging
Mice were administered with 100mg kg 1 NSC-134754 i.p. or left
untreated, and imaged either 6, 24 or 48 h later. Magnetic
resonance imaging was performed on a 7-T horizontal bore
Bruker microimaging system using a 3-cm birdcage coil.
Anaesthesia was induced by intraperitoneal injection of fentanyl
citrate (0.315mgml 1) plus fluanisone (10mgml 1 (Hypnorm;
Janssen Pharmaceutical Ltd., High Wycombe, UK)), midazolam
(5mgml 1 (Hypnovel; Roche)), and water (1 : 1 : 2). A lateral tail
vein was cannulated with a 27-G butterfly catheter (Hospira, Royal
Leamington Spa, Warwickshire, UK) for remote administration of
the contrast agent Gd-DTPA (Magnevist, Schering, Berlin,
Germany). Mice were positioned supine in the coil, and their core
temperature was maintained at 37 1C with warm air blown through
the magnet bore. Multi-slice T2-weighted contiguous 1-mm thick
axial images were first acquired for localisation of the tumour and
subsequent quantitation of tumour volume. A diffusion-weighted
(DW) spin-echo sequence (TR¼ 1500ms, b-value¼ 150–750
smm 2, 4 b-values, 1 average) was then used to determine the
tumour apparent diffusion coefficient (ADC) from a single 1-mm
thick axial slice through the centre of the tumour. Dynamic
contrast-enhanced MRI data were then acquired from the same
slice using an inversion recovery (IR) trueFISP sequence with one
baseline scan (TI¼ 130–2592ms, 20 inversion times, TR¼ 4ms,
TE¼ 2ms, 12 averages) and 75 dynamic scans (TI¼ 130–1037ms,
8 inversion times, TR¼ 4ms, TE¼ 2ms, temporal resolution¼ 9 s,
2 averages) before and following i.v. injection of 0.1mmol kg 1
Gd-DTPA (Boult et al, 2011). Immediately following MRI, the
hypoxia marker pimonidazole (60mg kg 1; Hypoxyprobe Inc.,
Burlington, VT, USA) was administered intraperitoneally (Raleigh
et al, 1999). After 45min, Hoechst 33342 (15mg kg 1; Sigma-
Aldrich), a marker for perfused vessels (Smith et al, 1988), was
injected via a lateral tail vein. After 1min tumours were rapidly
excised, and cut threeways; two-thirds were snap frozen over
liquid nitrogen for subsequent fluorescence microscopy and VEGF
analysis, respectively, while the remaining third was fixed in 10%
formal saline (v/v) for embedding in paraffin.
Magnetic resonance imaging data analysis
Diffusion-weighted and DCE-MRI data were fitted on a pixel-by-
pixel basis using in-house software (ImageView, developed in IDL,
ITT Visual Information Systems, Boulder, CO, USA). Diffusion
data were fitted using a Bayesian maximum a posteriori approach
that took into account the Rician distribution of noise in
magnitude MR data and provided estimates of the ADC, allowing
the median ADC value in each tumour to be calculated (Walker-
Samuel et al, 2009). Inversion recovery trueFISP data were fitted
using a similar approach, but which also utilised the dual-
relaxation sensitivity (T1 and T2) of the IR-trueFISP sequence and
incorporated the Tofts and Kermode pharmacokinetic model
(Boult et al, 2011). This provided estimates of Ktrans, dependent on
permeability, blood flow and blood volume. T2-weighted images
were segmented using hand-drawn regions of interest (ROIs) to
allow quantitation of tumour volumes to be calculated.
Immunofluorescence/histochemical analysis
For immunofluorescence, serial 10mm frozen tissue sections were cut,
and slides fixed in ice-cold acetone for 10min before being imaged on
a fluorescence microscope for Hoechst 33342 uptake. Fluorescence
signals from tumour sections were then recorded at 365nm using a
motorised scanning stage (Prior Scientific Instruments, Cambridge,
UK) attached to a BX51 microscope driven by image analysis
software (CellP). Immediately following Hoechst 33342 image
acquisition, the slides were blocked with 2% bovine serum albumin
(w/v) (Vector) and 5% goat serum albumin (v/v) (Sigma-Aldrich) in
PBS for 30min, followed by incubation for 2h with a FITC-
conjugated mouse anti-pimonidazole antibody protected from light
(Hypoxyprobe Inc., 1 : 500). The slides were then washed and imaged
at 450–490nm. All slides were then stained with haematoxylin and
eosin (H&E), dehydrated through a series of alcohols and xylene,
coverslipped and imaged under bright field illumination.
Paraffin-embedded tissue was cut into 5mm sections, dewaxed and
rehydrated through xylene and graded alcohols. Antigen retrieval
was performed using the microwave heat-induced method with
10mM citrate buffer (pH 6.0) for 20min (Shi et al, 1991). Slides
were then blocked for 1h with serum-free protein block (Dako, Ely,
UK), incubated overnight with either rabbit anti-human HIF-1a
(Abcam, Cambridge, UK, 1 : 100) or rabbit anti-human GLUT-1
(Millipore, 1 : 100). The following day, slides were washed twice and
incubated for 15min with peroxidase block (Dako) to quench
endogenous peroxidase activity. After further washes, an anti-rabbit
HRP polymer (Dako) was applied to slides and after a 40-min
incubation, staining was visualised using 3,3-diaminobenzidineþ
(Dako). Sections were counterstained with Mayer’s haematoxylin,
dehydrated through graded alcohols and mounted.
Image analysis software (CellP) was used for all image post-
processing. For perfused vessels (Hoechst 33342), tumour hypoxia
(pimonidazole) and necrosis (H&E), two/three sections per tumour
from a minimum of four tumours from each treatment group were
analysed. Regions of interest for each tumour section were defined
and an intensity threshold level set per tumour to account for
variation in staining. Fluorescence particles were detected and
expressed as a mean percentage of each tumour section. For the
quantitation of Hoechst 33342 perfused area and pimonidazole
adducts, the H&E composite image was used to exclude any residual
glandular prostate tissue and necrosis from analysis. For GLUT-1
and HIF-1a analysis, 12 fields of view from a minimum of four
tumours from each group were assessed and scored using a semi-
quantitative method. Glucose transporter-1 membrane staining was
scored as follows: 0¼ absence of staining, 1¼o10% staining,
2¼o50% staining, 3¼450% staining (Mayer et al, 2004). For
HIF-1a analysis, positive expression was defined by nuclear staining
and scored as follows: 0¼ absence of staining, 1¼o25% staining,
2¼ 25–50% staining, 3¼ 50–75% staining, 4¼475% staining.
VEGF protein analysis
A minimum of four tumours from control, 6 and 24 h treatment
groups were analysed. Snap frozen tumours were ground using a
bead grinder homogeniser (Precellys, Stretton Scientific, Derby-
shire, UK) in freshly prepared lysis buffer. Samples were
subsequently assessed for total protein concentration using the
Bradford method according to the manufacturer’s instructions
(Pierce Protein Research Products, Thermo Fisher Scientific,
Cramlington, UK) and human VEGF concentration per mg of
total protein was determined by ELISA (R&D Systems, Abingdon,
UK), according to the manufacturer’s protocol.
Statistical analysis
Statistical significance was defined as a P-value o0.05. Two-tailed
Student’s t-test, one-way ANOVA or Kruskal–Wallis with Bonfer-
roni correction were used where appropriate.
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RESULTS
NSC-134754 reduces hypoxia-induced HIF-1a protein
expression and the target gene GLUT-1 in vitro
The SRB assay was used to determine any anti-proliferative effects
of NSC-134754 on PC-3LN5 cells in vitro. A GI50 value of
E1.5 mmol l 1 after treatment for 72 h in hypoxia (1% O2) was
established. To determine whether the anti-proliferative effect of
NSC-134754 was related to HIF-1a protein levels, western blot
analysis of 1 , 3 and 5 GI50 were performed on PC-3LN5
cells incubated for 6 or 24 h in hypoxia. NSC-134754 reduced HIF-
1a protein expression in a dose-dependent manner, with complete
inhibition seen at 6 h and decreased expression at 24 h with 5
GI50 (Figure 1A). The effect of NSC-134754 on GLUT-1, a major
downstream target of HIF-1 and a membrane-bound protein
involved in intracellular glucose transport, was also examined.
Western blot analysis demonstrated a reduction in GLUT-1
expression (3 and 5 GI50) after 6 and 24 h in hypoxia
(Figure 1B). Immunocytofluorescence confirmed control cells
exposed to hypoxic conditions for 6 and 24 h exhibited strong
GLUT-1 membranous staining with diffuse cytoplasmic staining,
which was particularly evident at 24 h. In cells treated with NSC-
134754 (5 GI50) for 6 or 24 h in hypoxia, an overall decrease in
GLUT-1 staining compared with control cells was apparent
(Figure 1C). The DAPI-stained nuclei were morphologically similar
between control and treated cells, with negligible chromatin
condensation and/or nuclear fragmentation (Figure 1C).
NSC-134754 alters cellular metabolism and downregulates
LDH-A and c-Myc protein expression in vitro
High-resolution 1H-MRS was used to assess the biochemical effects
of decreased GLUT-1 expression with NSC-134754 in vitro.
Aqueous extracts of cells and conditioned media treated with
NSC-134754 (5 GI50) and exposed to 24 h hypoxia (1% O2) were
analysed. Representative 1H-MRS spectra of cell extracts with
metabolic changes induced by NSC-134754 are shown in
Figure 2A. Conditioned media from treated cells showed a
statistically significant decrease in glucose consumption
(Po0.05) and lactate production (Po0.05) compared with control
cells (also incubated in hypoxia). Intracellular lactate concentra-
tion was not significantly different between groups (Figure 2C).
However, treatment with NSC-134754 significantly increased
intracellular glucose by 44-fold compared with controls
(Po0.01) (Figure 2B and C). Other metabolites of note were (i)
glutamine and glutamate, both of which were significantly
increased in uptake from conditioned media and had significantly
increased intracellular levels in NSC-134754-treated cells com-
pared with controls (Po0.05) and (ii) intracellular choline
metabolites, of which a highly significant (Po0.01) increase in
glycerophosphocholine and significant (Po0.05) decrease in
phosphocholine was determined in the treated cells (data not
shown). The effect of NSC-134754 on LDH-A, a HIF-regulated
enzyme involved in the conversion of pyruvate to lactate, was also
determined (Dang and Semenza, 1999). In addition c-Myc, a proto-
oncogene previously reported to stimulate mitochondrial metabo-
lism, was assessed (Wise et al, 2008). Western blot analysis
demonstrated both a reduction in LDH-A expression and c-Myc
expression (5 GI50) after 6 and 24 h in hypoxia compared with
untreated control (Figure 2D).
NSC-134754 increases tumour water diffusion at 24 h
followed by tumour necrosis at 48 h
We next investigated the acute effects of a single i.p. dose of
100mg kg 1 NSC-134754 in vivo using DW-MRI. There was no
significant difference in mean tumour volume between the
treatment groups or the control group (P40.1). Representative
ADC maps calculated for control and treated mice are shown in
Figure 3A. Median ADC values for individual tumours are shown
in Figure 3B. Tumour ADC was significantly higher 24 and 48 h
post-treatment with NSC-134754 (Po0.05 and Po0.01, respec-
tively) compared with control and 6 h post-treatment groups.
Morphological assessment using H&E demonstrated a central core
of necrosis as a general feature of PC-3LN5 tumours at the time of
treatment/imaging (Figure 3C). Quantitative analysis revealed an
associated increase in necrosis 24 h after administration with NSC-
134754 (P¼ 0.17), with a statistically significant increase at 48 h
post-treatment (Po0.05) compared with control (Figure 3D).
NSC-134754 induces a transient decrease in HIF-1a
followed by a sustained decrease in GLUT-1
The translational effects of a single i.p. dose of 100mg kg 1 NSC-
134754 on the HIF pathway in PC-3LN5 orthotopic prostate
tumours were assessed. Cytoplasmic expression of HIF-1a was
present throughout all tumours, while nuclear staining was
particularly evident in peri-necrotic zones (Figure 4A). Nuclear
HIF-1a was temporally and significantly lower in treated tumours
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Figure 1 Molecular effects of NSC-134754 on the HIF pathway in
PC-3LN5 cells in vitro exposed to hypoxia (1% O2) for 6 or 24 h.
Representative western blots showing (A) HIF-1a expression (1 , 3
and 5 GI50) and (B) GLUT-1 expression (3 and 5 GI50).
(C) Immunocytofluorescence expression of GLUT-1 (5 GI50). For
internal positive control, lysates from cells incubated for 16 h with the
hypoxia mimetic deferoxamine (HIF-1a) and normal murine brain tissue
(GLUT-1) were used.
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at 6 h compared with control (Po0.05). After 24 h, HIF-1a staining
between the groups was comparable (Figure 4B). The HIF-1 target
gene, GLUT-1, demonstrated similar patterns of membranous
expression in the 6, 24 and 48 h post-treatment tumours. In
contrast, control tumours exhibited strong, diffuse GLUT-1
expression throughout (Figure 4A). Glucose transporter-1 expres-
sion was significantly lower in treated tumours at 24 h compared
with control (Po0.01), and continued to be downregulated for at
least 48 h (Po0.01) (Figure 4B). No significant difference in
tumour VEGF, assayed by ELISA, was found between the treatment
groups (Figure 4B).
NSC-134754 is associated with a transient increase in
tumour hypoxia that precedes an increase in tumour
necrosis, and is independent of changes in vessel perfusion
Given the intrinsic role of the HIF pathway in cellular adaptation
to hypoxia, we also investigated the vascular and oxygenation
status of tumours. Dynamic contrast-enhanced MRI was used to
estimate Ktrans, a compound imaging biomarker of both vascular
permeability and blood flow (Leach et al, 2005). No significant
difference in Ktrans was determined at either 6 or 24 h following
treatment with NSC-134754 compared with controls (data not
shown). Ex-vivo composite images of hypoxia and perfusion for
representative tumours from control, 6, 24 and 48 h treated mice
are shown in Figure 5A. Tumour hypoxia was determined with
pimonidazole staining, a 2-nitroimidazole that forms bioreductive
adducts at typically o10mmHg (Raleigh et al, 1999). After 6 h of
treatment with NSC-134754, mean percentage pimonidazole
adduct formation was not significantly different in treated vs
control groups. At 24 h, the mean percentage pimonidazole adduct
area was significantly greater in treated mice compared with
controls (Po0.05). At 48 h post-treatment, no statistical signifi-
cance in mean percentage pimonidazole adduct formation
compared with controls was observed (Figure 5B). Vessel
perfusion, measured using Hoechst 33342, did not significantly
differ between control, 6, 24 and 48 h treated tumours (Figure 5B).
DISCUSSION
Tumour hypoxia represents a major obstacle to the treatment
success of radiotherapy and certain types of chemotherapy (Tatum
et al, 2006). In response to hypoxia, HIF-1 activates the
transcription of genes whose protein products are involved in cell
survival, angiogenesis, glycolytic metabolism and cell invasion/
metastasis (Semenza, 2003). Small-molecule inhibitors that target
components of the HIF pathway are thus being pursued as an anti-
cancer strategy. In the present study, we have investigated the
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Figure 2 PC-3LN5 cells were incubated in hypoxia (1% O2) for 24 h± 5 GI50 NSC-134754. (A) Representative 1H-MRS spectrum of a cell extract
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media following treatment with NSC-134754, expressed as a percentage of untreated control. Results are expressed as mean percentage of control±1
s.e.m., *Po0.05, **Po0.01, nX3. (D) Western blots showing the effects of NSC-134754 on c-Myc and LDH-A protein expression after 6 and 24 h
treatment in hypoxia compared with untreated control.
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acute effects of the small-molecule HIF-pathway inhibitor NSC-
134754 on human prostate cancer cells in vitro and murine
orthotopic prostate tumours in vivo. Previous studies have
demonstrated that HIF inhibition results in metabolic reprogram-
ming, with an attenuation of anaerobic glycolysis and an increase
in mitochondrial metabolism (Cairns et al, 2007). Here, we have
shown that treatment with NSC-134754 alters the metabolic profile
of PC-3LN5 cells, downregulating GLUT-1 and LDH-A, resulting in
an overall reduction in glucose consumption and lactate produc-
tion. These findings are in agreement with the metabolic response
to pharmacological HIF inhibition reported by others (Jordan et al,
2005a; Moeller et al, 2005). We also show that this NSC-134754-
induced downregulation in glycolytic metabolism was accompa-
nied by an increase in glutamine/glutamate metabolism. Cellular
uptake of glutamine can be used for protein synthesis, but is
primarily converted to glutamate, which is further catabolised to
a-ketoglutarate for further oxidation in the tricarboxylic acid
(TCA) cycle. Recent studies have suggested that the proto-
oncogene c-Myc is a major mediator in stimulating mitochondrial
glutaminolysis (Wise et al, 2008). Furthermore, an associative
relationship between HIF-1 and c-Myc has also been demon-
strated, whereby c-Myc and HIF-1 co-operate to accelerate both
glycolysis and angiogenesis (Kim et al, 2007). We thus sought to
determine whether the effect of HIF inhibition (and associated
metabolic changes) influenced c-Myc protein expression. PC-3LN5
cells strongly expressed c-Myc protein under conditions of
hypoxia. Interestingly, treatment with NSC-134754 induced almost
complete suppression of c-Myc protein expression. Taken
together, NSC-134754 appears to exhibit dual-activity against both
the HIF pathway and c-Myc. Further studies will be required in
order to determine the mechanism of HIF/c-Myc protein repres-
sion, particularly to address whether these effects are synergistic or
independently produced.
Many glycolytic enzymes are known to be gene targets of HIF-1
(Semenza, 2003). Thus, a reduction in the availability of, for
example, hexokinase 1/2 and/or glyceraldehyde 3-phosphate
dehydrogenase, could conceivably lead to a downregulation in
glycolysis and subsequent increase in glucose. We observed a
significant increase in intracellular glucose following treatment
with NSC-134754. To our knowledge, increased intracellular
glucose with a small-molecule inhibitor of the HIF pathway is a
novel finding. Increased intracellular glucose, coupled with
decreased glucose uptake, has been reported with the tyrosine
kinase inhibitor imatinib (Klawitter et al, 2009). Notably, imatinib
has also been shown to (indirectly) downregulate HIF-1 (Litz and
Krystal, 2006). In contrast, maintenance of basal intracellular
glucose has been shown to act as an anti-apoptotic survival
mechanism (Weihua et al, 2008). Following treatment with NSC-
134754, our observations were of a reduction in cellular prolifera-
tion, with no associated evidence of nuclear morphology
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characteristics of cellular death. Further studies will be required to
elucidate the functional relevance of this finding, particularly with
respect to therapeutic response. The impact of increased
intracellular glucose on modalities based on the imaging of
analogues of glucose (e.g., 18F fluorodeoxyglucose positron
emission tomography) will also be of relevance.
A number of alterations in metabolites known to be involved in
lipid synthesis and turnover were also observed following
treatment with NSC-134754. These included a significant reduction
in phosphocholine and highly significant increase in glyceropho-
sphocholine. High levels of phosphocholine have been associated
with increased membrane synthesis, a feature associated with
rapidly dividing cancer cells (Moreno and Aru´s, 1996). Conversely,
decreased phosphocholine accompanied with increased glycero-
phosphocholine has been reported with several molecularly
targeted therapies (Beloueche-Babari et al, 2010). Overall, the
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Figure 4 Targeted and transcriptional effects of NSC-134754 on PC-3LN5 murine orthotopic prostate tumours at 6, 24 and 48 h after treatment
compared with untreated control. (A) Representative images of HIF-1a and GLUT-1 expression. (B) Summary of mean differences in expression of
tumour HIF-1a, GLUT-1 and VEGF in NSC-134754-treated groups compared with control: K HIF-1a, m GLUT-1, ’ VEGF. Values are represented as
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Figure 5 Microenvironmental effects of NSC-134754 on murine orthotopic PC-3LN5 prostate tumours at 6, 24 and 48 h after treatment compared
with untreated controls. (A) Representative composite fluorescence images demonstrating vessel perfusion (Hoechst 33342, blue) and hypoxia
(pimonidazole adducts, green). (B) Summary of the quantitative analysis of tumour perfusion and hypoxia over time. Values are represented as
mean±1 s.e.m., *Po0.05 compared with control.
Response to the HIF-pathway inhibitor NSC-134754
LCJ Baker et al
1644
British Journal of Cancer (2012) 106(10), 1638 – 1647 & 2012 Cancer Research UK
T
ra
n
sla
tio
n
a
l
T
h
e
ra
p
e
u
tic
s
alterations in lipid metabolites induced with treatment suggest
additional anti-cancer activity associated with NSC-134754
in vitro.
We sought to determine whether the metabolic changes and
anti-proliferative effects of NSC-134754 observed in vitro would
translate to anti-tumour effects in vivo. Typically, tumour ADC
(measured using non-invasive MRI) is increased following
successful anti-cancer therapy, and is associated with a loss in
membrane integrity, an early feature of cellular death (before
measurable changes in tumour volume) (Zhao et al, 1996;
Chenevert et al, 2000; Padhani et al, 2009). Increased ADC has
also been reported as an early response to the pharmacological
HIF-1a inhibitor PX-478, presumably due to an increase in tumour
necrosis (Jordan et al, 2005b). We have demonstrated that tumour
ADC was significantly greater 24 and 48 h post-treatment with
NSC-134754 compared with control. Importantly, the elevated
ADC determined 24 h post-treatment preceded any histologically
determined significant increase in tumour necrosis, which was
reached 48 h post-treatment. This early, anti-tumourigenic
response to NSC-134754 is also comparable with the time course
of ADC changes reported pre-clinically with PX-478 (Jordan et al,
2005b). The mechanism(s) underlying decreased tumour cellular-
ity with HIF inhibition are not yet understood, and given the
pleiotropic effects that HIF inhibition likely elicits, will require
extensive investigation. Nevertheless, DW-MRI appears to provide
a non-invasive imaging approach in which to detect acute response
to HIF inhibition.
Dynamic contrast-enhanced MRI has previously been shown to
detect early effects of HIF inhibition on tumour vessel physiology
and vascular flow (Jordan et al, 2005b). Using DCE-MRI, we were
unable to demonstrate any anti-angiogenic or inhibitory effects on
vessel perfusion with NSC-134754. This surprising finding may be
attributed to differences in dose/response timings and/or the type
of MR-contrast agent used. For example, we utilised the clinically
approved low molecular weight gadolinium contrast agent
Magnevist, sensitive to changes in both vascular permeability
and perfusion, whereas others have used a macromolecular
contrast agent providing greater sensitivity to alterations in
vascular permeability alone (Jordan et al, 2005b). Ex-vivo
techniques to measure vessel perfusion and tumour VEGF were
also in agreement with our DCE-MRI findings, with no anti-
angiogenic response induced with NSC-134754. It should be noted
that HIF-independent pathways may contribute to angiogenesis
when the HIF pathway is blocked. For example, the resultant
accumulation of hydrogen peroxide increases NF-kB, resulting in
the upregulation of the pro-angiogenic factors angiopoietin-2 and
VEGF (Mizukami et al, 2007). Thus other mechanisms, aside from
HIF, may regulate tumour vascularity in the PC-3LN5 model.
Importantly, and despite an absence of change in vascular
perfusion, an increase in tumour hypoxia was detected 24 h post-
treatment with NSC-134754. Although HIF inhibition has been
shown to increase tumour hypoxia due to changes in blood flow,
perfusion and tumour VEGF concentrations (Harada et al, 2009),
targeting HIF-1 (or components of the HIF pathway) has also been
shown to increase mitochondrial metabolism, which in turn
increases the rate of oxygen consumption (Cairns et al, 2007).
Increased mitochondrial metabolism in malignant cells increases
the generation of reactive oxygen species, which are linked to
cellular death (Le et al, 2010). The increase in tumour hypoxia with
NSC-134754, independent of changes in vascular function, suggests
that the anti-tumour activity of this agent may be primarily
metabolically driven. Thus, NSC-134754 may increase tumour
hypoxia via utilisation of a non-glycolytic energy source, exhaust-
ing available oxygen through the TCA cycle, and ultimately leading
to an increase in tumour necrosis. Interestingly, though acute
vascular effects were reported with the HIF-1a inhibitor PX-478,
these appeared to be superceded by metabolic changes, suggesting
that the overall therapeutic effect of HIF inhibition with PX-478
was also metabolically derived (Welsh et al, 2004). Collectively,
these data suggest that the evaluation of novel HIF inhibitors will
benefit from both 1H-MRS and MRI investigations.
Finally, increased expression of HIF-1a and the downstream
target GLUT-1 have been associated clinically with tumour
metastasis and poor prognosis (Younes et al, 1997; Haber et al,
1998; Zhong et al, 1999). We have confirmed that NSC-134754
exhibits both targeted and translational effects in vivo via ex vivo
detection of HIF-1a and GLUT-1. Using immunohistochemistry,
we have demonstrated that a single i.p. dose of NSC-134754
decreases HIF-1a expression for at least 6 h. Furthermore, the
temporal increase in tumour hypoxia induced in treated tumours
at 24 h was not accompanied by a subsequent increase in HIF-1a
expression compared with controls. This may indicate that NSC-
134754 maintains a dampened hypoxia-induced HIF response in
the PC-3LN5 model for at least 24 h after administration.
Membrane expression of the downstream target GLUT-1 was
decreased 24 h post-NSC-134754. Interestingly, this decrease was
sustained out to 48 h, providing further evidence of the potent
metabolic effects of this agent. A similar temporal response
in GLUT-1 expression has also been reported with PX-478
(Welsh et al, 2004).
In conclusion, HIF-pathway inhibitors are an emerging class of
therapeutics that offer great potential, but are also beginning to
reveal the complexity underlying tumour growth and survival in
the hypoxic microenvironment. The cascade of gene transcription
downstream of HIF-1 impacts on angiogenic, metabolic, prolif-
erative and metastatic pathways, thus HIF-pathway inhibitors in
turn may exhibit a wide range of effects. The results reported here
demonstrate that the small-molecule HIF-pathway inhibitor NSC-
134754 induces metabolic reprogramming in vitro, and acute
functional changes independent of vascular effects in vivo.
Importantly, the early, anti-tumour effects of NSC-134754 were
observed non-invasively with DW-MRI. Quantitation of tumour
ADC thus appears to be an attractive, clinically translatable
imaging biomarker sensitive to therapeutic response to HIF-
pathway inhibition. Further investigation into the action of NSC-
134754 will be required in order to determine the utility of this
compound, either as a single agent or in combination. In
particular, the timing of the microenvironmental effects of NSC-
134754 and those of other potential HIF inhibitors will be an
important factor to consider when combining these types of agents
with treatment regimens that are reliant on tumour oxygenation
levels, for example, radiotherapy.
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